Researchers from the University of Guadalajara reported on Jul. 22 that bee venom may improve the therapeutic effects of standard Parkinson's disease treatment in a mouse model. The study, published in Neuroprotection on May 20, involved combining freeze-dried bee venom with levodopa and carbidopa, which are commonly used to manage symptoms of Parkinson's disease.
Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons, leading to motor symptoms such as tremors and rigidity as well as cognitive decline. While levodopa combined with carbidopa remains the primary treatment for alleviating these symptoms, its effectiveness often decreases over time and can result in complications including motor fluctuations and dyskinesias.
The research team led by Professor Alma Karen Lomeli-Lepe aimed to determine if bee venom could enhance the benefits of this standard therapy. "We aimed to explore whether bee venom could potentiate the effects of standard therapy in a 6-hydroxydopamine (6-OHDA) model of Parkinson's disease," said Lomeli-Lepe. The study used adult male CD-1 mice divided into groups: healthy controls, untreated Parkinsonian mice, those treated with L-DOPA/carbidopa alone, and those given both L-DOPA/carbidopa plus freeze-dried bee venom.
Results showed that mice receiving both therapies maintained near-normal forelimb symmetry and had less paw dragging compared to those treated only with L-DOPA/carbidopa. In addition to improved motor performance, combination-treated mice also retained their ability to recognize novel objects during memory assessments—a benefit not seen in untreated animals or those receiving only standard therapy. The combination also produced strong recovery in lateralized motor behavior during corridor tasks.
The researchers noted that their evaluation focused solely on behavioral outcomes without directly assessing dopaminergic neuron survival or molecular markers related to inflammation or oxidative stress. As such, they said further studies are needed to clarify how bee venom produces these observed improvements.
"Our findings demonstrate promising behavioral benefits of bee venom as an adjunct to L-DOPA/carbidopa therapy, but further research is needed to understand the underlying mechanisms," said Lomeli-Lepe.
